Stockreport

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]

Acrivon Therapeutics, Inc.  (ACRV) 
PDF 74%, clinical benefit 65%), compared with a 22% response rate in non-serous tumors; the biomarker-positive intent-to-treat group had a 39% ORR and 81% DCR. The study u [Read more]